Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover QT evaluation study of APL-130277 in Parkinson's disease with OFF episodes
2016-001762-29Phase 2Completed
- Sponsor
- Sunovion
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apomorphine in Parkinson's disease (PD) (3 arms), sponsored by Sunovion. Primary endpoint: Time-matched change from baseline in QTc, placebo-adjusted and heart-rate corrected. Started May 2017; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-001762-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001762-29.